Cargando…

Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent

OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hoogstraten, Lisa M.C., Witjes, J. Alfred, Meijer, Richard P., Ripping, Theodora M., Kiemeney, Lambertus A., Aben, Katja K.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790563/
https://www.ncbi.nlm.nih.gov/pubmed/35064953
http://dx.doi.org/10.1111/bju.15697
_version_ 1784859206297321472
author van Hoogstraten, Lisa M.C.
Witjes, J. Alfred
Meijer, Richard P.
Ripping, Theodora M.
Kiemeney, Lambertus A.
Aben, Katja K.H.
author_facet van Hoogstraten, Lisa M.C.
Witjes, J. Alfred
Meijer, Richard P.
Ripping, Theodora M.
Kiemeney, Lambertus A.
Aben, Katja K.H.
author_sort van Hoogstraten, Lisa M.C.
collection PubMed
description OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND METHODS: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). RESULTS: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. CONCLUSION: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment.
format Online
Article
Text
id pubmed-9790563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97905632022-12-28 Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent van Hoogstraten, Lisa M.C. Witjes, J. Alfred Meijer, Richard P. Ripping, Theodora M. Kiemeney, Lambertus A. Aben, Katja K.H. BJU Int Original Articles OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND METHODS: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). RESULTS: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. CONCLUSION: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment. John Wiley and Sons Inc. 2022-02-08 2022-12 /pmc/articles/PMC9790563/ /pubmed/35064953 http://dx.doi.org/10.1111/bju.15697 Text en © 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
van Hoogstraten, Lisa M.C.
Witjes, J. Alfred
Meijer, Richard P.
Ripping, Theodora M.
Kiemeney, Lambertus A.
Aben, Katja K.H.
Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
title Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
title_full Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
title_fullStr Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
title_full_unstemmed Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
title_short Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
title_sort non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790563/
https://www.ncbi.nlm.nih.gov/pubmed/35064953
http://dx.doi.org/10.1111/bju.15697
work_keys_str_mv AT vanhoogstratenlisamc nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent
AT witjesjalfred nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent
AT meijerrichardp nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent
AT rippingtheodoram nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent
AT nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent
AT kiemeneylambertusa nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent
AT abenkatjakh nonmetastaticmuscleinvasivebladdercancertheroleofageinreceivingtreatmentwithcurativeintent